ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care

Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.

Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.

The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities

Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.

Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.

Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.

Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.

Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.